;PMID: 3485044 ;source_file_1018.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..39] = [t:0..39] ;1)sentence:[e:45..152] = [t:45..152] ;2)section:[e:156..179] = [t:156..178] ;3)sentence:[e:183..443] = [t:183..443] ;4)sentence:[e:444..583] = [t:444..583] ;5)sentence:[e:584..798] = [t:584..798] ;6)sentence:[e:799..892] = [t:799..892] ;7)sentence:[e:893..1059] = [t:893..1059] ;8)sentence:[e:1060..1139] = [t:1060..1139] ;9)sentence:[e:1140..1301] = [t:1140..1301] ;10)sentence:[e:1302..1421] = [t:1302..1421] ;11)section:[e:1425..1469] = [t:1425..1468] ;Sentence Matching Errors ;ERROR_Section end mismatch[e:156..179][t:156..178] ;ERROR_Section end mismatch[e:1425..1469][t:1425..1468] ;Token/POS Errors ;ERROR_Token in entity file but not tree[178..179] . ;ERROR_Token in entity file but not tree[1468..1469] ] ;section 0 Span:0..39 ;Endocrinology. 1986 Apr;118(4):1266-70. (SEC (FRAG (NNP:[0..13] Endocrinology) (IN:[13..14] .) (CD:[15..19] 1986) (DT:[20..28] Apr;118-LRB-) (CD:[28..30] 4-RRB-) (CD:[30..35] :1266) (::[35..36] -) (CD:[36..38] 70) (.:[38..39] .))) ;sentence 1 Span:45..152 ;The steroid C-17,20-lyase complex in isolated Graafian follicles: effects of ;human chorionic gonadotropin. ;[49..78]:cyp450:"steroid C-17,20-lyase complex" ;[123..151]:substance:"human chorionic gonadotropin" (SENT (NP-HLN (NP (NP (DT:[45..48] The) (NN:[49..56] steroid) (NN:[57..70] C-17,20-lyase) (NN:[71..78] complex)) (PP-LOC (IN:[79..81] in) (NP (JJ:[82..90] isolated) (JJ:[91..99] Graafian) (NNS:[100..109] follicles)))) (::[109..110] :) (NP (NP (NNS:[111..118] effects)) (PP (IN:[119..121] of) (NP (JJ:[123..128] human) (JJ:[129..138] chorionic) (NN:[139..151] gonadotropin)))) (.:[151..152] .))) ;section 2 Span:156..178 ;Eckstein B, Tsafriri A (SEC (FRAG (NNP:[156..164] Eckstein) (NNP:[165..166] B) (,:[166..167] ,) (NNP:[168..176] Tsafriri) (NN:[177..178] A))) (ORPH .) ;sentence 3 Span:183..443 ;Androstenedione synthesis was studied in isolated rat preovulatory follicles ;and compared with that of rat testicular tissue using [14C]progesterone ;together with 17 alpha-hydroxy-[3H]progesterone as substrates in the ;presence of NADH or NADPH as cofactors. ;[183..198]:substance:"Androstenedione" ;[315..332]:substance:"[14C]progesterone" ;[348..381]:substance:"17 alpha-hydroxy-[3H]progesterone" ;[385..395]:substance:"substrates" ;[415..419]:substance:"NADH" ;[424..429]:substance:"NADPH" ;[433..442]:substance:"cofactors" (SENT (S (NP-SBJ-1 (NN:[183..198] Androstenedione) (NN:[199..208] synthesis)) (VP (VBD:[209..212] was) (VP (VP (VBN:[213..220] studied) (NP-1 (-NONE-:[220..220] *)) (PP-LOC (IN:[221..223] in) (NP (JJ:[224..232] isolated) (NN:[233..236] rat) (JJ:[237..249] preovulatory) (NNS:[250..259] follicles)))) (CC:[260..263] and) (VP (VBN:[265..273] compared) (NP-1 (-NONE-:[273..273] *)) (PP-CLR (IN:[274..278] with) (NP (NP (DT:[279..283] that)) (PP (IN:[284..286] of) (NP (NN:[287..290] rat) (JJ:[291..301] testicular) (NN:[302..308] tissue))))) (S-MNR (NP-SBJ (-NONE-:[308..308] *)) (VP (VBG:[309..314] using) (NP (NP (NN:[315..332] -LSB-14C-RSB-progesterone)) (PP (ADVP (RB:[333..341] together)) (IN:[343..347] with) (NP (CD:[348..350] 17) (NN:[351..381] alpha-hydroxy--LSB-3H-RSB-progesterone)))) (PP (IN:[382..384] as) (NP (NNS:[385..395] substrates))) (PP (IN:[396..398] in) (NP (NP (DT:[399..402] the) (NN:[403..411] presence)) (PP (IN:[412..414] of) (NP (NP (NN:[415..419] NADH) (CC:[420..422] or) (NN:[424..429] NADPH)) (PP (IN:[430..432] as) (NP (NNS:[433..442] cofactors)))))))))))) (.:[442..443] .))) ;ERROR_Orphan Text from Tree File[178..183] . ;sentence 4 Span:444..583 ;The amount of androstenedione formed was measured by addition of carrier, ;reisolation, and crystallization to constant specific activity. ;[458..473]:substance:"androstenedione" (SENT (S (NP-SBJ-1 (NP (NP (DT:[444..447] The) (NN:[448..454] amount)) (PP (IN:[455..457] of) (NP (NN:[458..473] androstenedione)))) (VP (VBD:[474..480] formed) (NP (-NONE-:[480..480] *)))) (VP (IN:[481..484] was) (VP (VBN:[485..493] measured) (NP-1 (-NONE-:[493..493] *)) (PP-MNR (IN:[494..496] by) (NP (NP (NP (NN:[498..506] addition)) (PP (IN:[507..509] of) (NP (NN:[510..517] carrier)))) (,:[517..518] ,) (NP (NN:[519..530] reisolation)) (,:[530..531] ,) (CC:[532..535] and) (NP (NP (NN:[536..551] crystallization)) (PP (TO:[552..554] to) (NP (JJ:[555..563] constant) (JJ:[564..572] specific) (NN:[574..582] activity)))))))) (.:[582..583] .))) ;sentence 5 Span:584..798 ;The labeling patterns of androstenedione and 17 alpha-hydroxyprogesterone ;(17-OHP) confirmed that both tissues preferentially catalyzed the synthesis ;of androstenedione from progesterone rather than from 17-OHP. ;[609..624]:substance:"androstenedione" ;[629..658]:substance:"17 alpha-hydroxyprogesterone" ;[660..666]:substance:"17-OHP" ;[739..754]:substance:"androstenedione" ;[760..772]:substance:"progesterone" ;[791..797]:substance:"17-OHP" (SENT (S (NP-SBJ (NP (DT:[584..587] The) (VBG:[588..596] labeling) (NNS:[597..605] patterns)) (PP (IN:[606..608] of) (NP (NP (NN:[609..624] androstenedione)) (CC:[625..628] and) (NP (NP (CD:[629..631] 17) (NN:[633..658] alpha-hydroxyprogesterone)) (NP (-LRB-:[659..660] -LRB-) (NN:[660..666] 17-OHP) (-RRB-:[666..667] -RRB-)))))) (VP (VBD:[668..677] confirmed) (SBAR (IN:[678..682] that) (S (NP-SBJ (DT:[683..687] both) (NNS:[688..695] tissues)) (ADVP (RB:[696..710] preferentially)) (VP (VBD:[712..721] catalyzed) (NP (NP (DT:[722..725] the) (NN:[726..735] synthesis)) (PP (IN:[736..738] of) (NP (NN:[739..754] androstenedione))) (PP (PP (IN:[755..759] from) (NP (NN:[760..772] progesterone))) (CONJP (RB:[773..779] rather) (IN:[780..784] than)) (PP (IN:[785..789] from) (NP (NN:[791..797] 17-OHP))))))))) (.:[797..798] .))) ;sentence 6 Span:799..892 ;It appears, therefore, that free 17-OHP was not an obligatory intermediate ;in this reaction. ;[832..838]:substance:"17-OHP" (SENT (S (NP-SBJ (PRP:[799..801] It)) (VP (VBZ:[802..809] appears) (,:[809..810] ,) (ADVP (RB:[811..820] therefore)) (,:[820..821] ,) (SBAR (IN:[822..826] that) (S (NP-SBJ (JJ:[827..831] free) (NN:[832..838] 17-OHP)) (VP (VBD:[839..842] was) (RB:[843..846] not) (NP-PRD (DT:[847..849] an) (JJ:[850..860] obligatory) (NN:[862..874] intermediate)) (PP (IN:[875..877] in) (NP (DT:[878..882] this) (NN:[883..891] reaction))))))) (.:[891..892] .))) ;sentence 7 Span:893..1059 ;When hCG (5 IU) was administered sc and the follicles were isolated 3 h ;later, androstenedione synthesis was inhibited whether NADH or NADPH was ;added as cofactors. ;[898..901]:substance:"hCG" ;[903..904]:quantitative-value:"5" ;[905..907]:quantitative-units:"IU" ;[962..963]:quantitative-value:"3" ;[964..965]:quantitative-units:"h" ;[973..988]:substance:"androstenedione" ;[1022..1026]:substance:"NADH" ;[1030..1035]:substance:"NADPH" ;[1049..1058]:substance:"cofactors" (SENT (S (SBAR-ADV (WHADVP-2 (WRB:[893..897] When)) (S (S (NP-SBJ-1 (NN:[898..901] hCG) (PRN (-LRB-:[902..903] -LRB-) (NP (CD:[903..904] 5) (NN:[905..907] IU)) (-RRB-:[907..908] -RRB-))) (VP (VBD:[909..912] was) (VP (VBN:[913..925] administered) (NP-1 (-NONE-:[925..925] *)) (NP-ADV (NN:[926..928] sc)) (ADVP-2 (-NONE-:[928..928] *T*))))) (CC:[929..932] and) (S (NP-SBJ-3 (DT:[933..936] the) (NNS:[938..947] follicles)) (VP (VBD:[948..952] were) (VP (VBN:[953..961] isolated) (NP-3 (-NONE-:[961..961] *)) (NP (NP (CD:[962..963] 3) (NN:[964..965] h)) (ADVP-TMP (RB:[966..971] later)))))))) (,:[971..972] ,) (NP-SBJ-5 (NN:[973..988] androstenedione) (NN:[989..998] synthesis)) (VP (VBD:[999..1002] was) (VP (VBN:[1003..1012] inhibited) (NP-5 (-NONE-:[1012..1012] *)) (SBAR-ADV (VBN:[1014..1021] whether) (S (NP-SBJ-4 (NN:[1022..1026] NADH) (CC:[1027..1029] or) (NN:[1030..1035] NADPH)) (VP (VBD:[1036..1039] was) (VP (VBN:[1040..1045] added) (NP-4 (-NONE-:[1045..1045] *)) (PP (IN:[1046..1048] as) (NP (NNS:[1049..1058] cofactors))))))))) (.:[1058..1059] .))) ;sentence 8 Span:1060..1139 ;By contrast, 17-hydroxylase activity was inhibited only with NADH as ;cofactor. ;[1073..1087]:cyp450:"17-hydroxylase" ;[1122..1126]:substance:"NADH" ;[1130..1138]:substance:"cofactor" (SENT (S (PP (IN:[1060..1062] By) (NP (NN:[1063..1071] contrast))) (,:[1071..1072] ,) (NP-SBJ-1 (NN:[1073..1087] 17-hydroxylase) (NN:[1089..1097] activity)) (VP (VBD:[1098..1101] was) (VP (VBN:[1102..1111] inhibited) (NP-1 (-NONE-:[1111..1111] *)) (PP (RB:[1112..1116] only) (IN:[1117..1121] with) (NP (NP (NN:[1122..1126] NADH)) (PP (IN:[1127..1129] as) (NP (NN:[1130..1138] cofactor))))))) (.:[1138..1139] .))) ;sentence 9 Span:1140..1301 ;Hence, the gonadotropin, with NADH as cofactor, specifically reduced ;progesterone incorporation into androstenedione without affecting ;incorporation of 17-OHP. ;[1151..1163]:substance:"gonadotropin" ;[1171..1175]:substance:"NADH" ;[1179..1187]:substance:"cofactor" ;[1210..1222]:substance:"progesterone" ;[1243..1258]:substance:"androstenedione" ;[1294..1300]:substance:"17-OHP" (SENT (S (ADVP (RB:[1140..1145] Hence)) (,:[1145..1146] ,) (NP-SBJ (NP (DT:[1147..1150] the) (NN:[1151..1163] gonadotropin)) (,:[1163..1164] ,) (PP (IN:[1165..1169] with) (NP (NP (NN:[1171..1175] NADH)) (PP (IN:[1176..1178] as) (NP (NN:[1179..1187] cofactor)))))) (,:[1187..1188] ,) (ADVP (RB:[1189..1201] specifically)) (VP (VBD:[1202..1209] reduced) (NP (NP (NN:[1210..1222] progesterone) (NN:[1223..1236] incorporation)) (PP (IN:[1237..1241] into) (NP (NN:[1243..1258] androstenedione)))) (PP (IN:[1259..1266] without) (S-NOM (NP-SBJ (-NONE-:[1266..1266] *)) (VP (VBG:[1267..1276] affecting) (NP (NP (NN:[1277..1290] incorporation)) (PP (IN:[1291..1293] of) (NP (NN:[1294..1300] 17-OHP)))))))) (.:[1300..1301] .))) ;sentence 10 Span:1302..1421 ;Thus, hCG appears to affect androstenedione production from progesterone at ;two different sites of the lyase complex. ;[1308..1311]:substance:"hCG" ;[1331..1346]:substance:"androstenedione" ;[1363..1375]:substance:"progesterone" ;[1407..1420]:cyp450:"lyase complex" (SENT (S (ADVP (RB:[1302..1306] Thus)) (,:[1306..1307] ,) (NP-SBJ-1 (NN:[1308..1311] hCG)) (VP (VBZ:[1312..1319] appears) (S (NP-SBJ-1 (-NONE-:[1319..1319] *)) (VP (TO:[1320..1322] to) (VP (VB:[1324..1330] affect) (NP (NP (NN:[1331..1346] androstenedione) (NN:[1347..1357] production)) (PP (IN:[1358..1362] from) (NP (NN:[1363..1375] progesterone)))) (PP-LOC (IN:[1376..1378] at) (NP (NP (CD:[1379..1382] two) (JJ:[1383..1392] different) (NNS:[1393..1398] sites)) (PP (IN:[1399..1401] of) (NP (DT:[1403..1406] the) (NN:[1407..1412] lyase) (NN:[1413..1420] complex))))))))) (.:[1420..1421] .))) ;section 11 Span:1425..1468 ;PMID: 3485044 [PubMed - indexed for MEDLINE (SEC (FRAG (NNP:[1425..1429] PMID) (::[1429..1430] :) (CD:[1431..1438] 3485044) (-LRB-:[1439..1440] -LSB-) (NNP:[1440..1446] PubMed) (::[1447..1448] -) (VBN:[1449..1456] indexed) (IN:[1457..1460] for) (NNP:[1461..1468] MEDLINE))) ;ERROR_Orphan Text from EOF Tree File[1468..EOF] ] (ORPH -RSB-)